Tax

Tax Reconciliation, Foreign Rate Differential

Vertex Pharmaceuticals Tax Reconciliation, Foreign Rate Differential remained flat by 0.0% to $0.05 in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 3650.0%, from -$0.00 to $0.05. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement
SectionTax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2024

How to read this metric

A positive differential suggests the company benefits from lower-tax foreign jurisdictions, improving overall net margins.

Detailed definition

This metric measures the impact on the effective tax rate caused by the difference between the domestic statutory tax ra...

Peer comparison

A critical metric for global enterprises to explain deviations from the statutory tax rate.

Metric ID: is_cop_tax_reconciliation_foreign_rate_differential

Historical Data

2 years
 FY'23FY'24
Value-$0.01$0.21
YoY Change>999%
Range-$0.01$0.21
Avg YoY Growth>999%
Median YoY Growth>999%

Frequently Asked Questions

What is Vertex Pharmaceuticals's tax reconciliation, foreign rate differential?
Vertex Pharmaceuticals (VRTX) reported tax reconciliation, foreign rate differential of $0.05 in Q4 2024.
How has Vertex Pharmaceuticals's tax reconciliation, foreign rate differential changed year-over-year?
Vertex Pharmaceuticals's tax reconciliation, foreign rate differential increased by 3650.0% year-over-year, from -$0.00 to $0.05.
What does tax reconciliation, foreign rate differential mean?
The tax rate impact resulting from operating in countries with different tax rates than the home country.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.